The DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Accumulation of duct cells with activated YAP parallels fibrosis progression in non-alcoholic fatty liver disease
Open accessAbstract
Background & aims Mechanisms that regulate regeneration of injured livers are complex. YAP, a stem cell associated factor, controls liver growth in healthy adult mice. Increasing nuclear localization of YAP triggers accumulation of reactive-appearing ductular cells (YAP+RDC) with liver progenitor capabilities. The significance of YAP activation, and mechanisms involved, are unknown in diseased livers. We evaluated the hypothesis that YAP is more activated in injured livers that are scarring than in those that are regenerating effectively.Methods Immunohistochemistry and qRT-PCR analysis were used to localize and quantify changes in YAP and RDC in 52 patients with non-alcoholic fatty liver disease (NAFLD) and two mouse models of diet-induced non-alcoholic steatohepatitis (NASH). Results were correlated with liver disease severity, metabolic risk factors, and factors proven to control NAFLD progression.Results YAP increased in NAFLD where it mainly localized in nuclei of RDC that expressed progenitor markers. Accumulation of YAP+RDC paralleled the severity of hepatocyte injury and accumulation of Sonic hedgehog, but not steatosis or metabolic risk factors. YAP+RDC expressed osteopontin, a Shh-regulated fibrogenic factor. Myofibroblast accumulation, fibrosis, and numbers of YAP+RDC strongly correlated. In murine NASH models, atrophic fibrotic livers contained significantly more YAP+RDC than livers with less severe NASH.Conclusion YAP+RDC promote scarring, rather than effective regeneration, during NASH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Other major sources of hedgehog ligands may be reactive-appearing ductular cells that strongly correlate with fibrosis in patients with MASH or in MASH-associated hepatocytes where increased cholesterol intake activate TAZ to drive Indian hedgehog expression and secretion (112, 113, 163).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [163]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Follow-up report on the diagnosis of diabetes mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2003) · Diabetes Care · doi:10.2337/diacare.26.11.3160 · Cited by 3,784 · cited 1×
“Diabetes mellitus was defined as fasting blood glucose >126 mg/dl, or regular use of hypoglycemic medications [13].”
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287 · cited 5×
“Severity of liver fibrosis predicts liver-related morbidity and mortality [19], and strongly correlates with RDC accumulation, with both processes being”
InfluentialSingh, S., Allen, A. M., Wang, Z., Prokop, L. J., Murad, M. H., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.014 · Cited by 1,748
Regulation of the Hippo-YAP Pathway by G-Protein-Coupled Receptor Signaling
Yu, F.-X., Zhao, B., Panupinthu, N., Jewell, J. L., Lian, I., Wang, L. H., Zhao, J., Yuan, H., Tumaneng, K., Li, H., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.037 · Cited by 1,628 · cited 1×
“Recently, it was shown that phospholipids may induce YAP activation [35].”
YAP1 increases organ size and expands undifferentiated progenitor cells
Camargo, F. D., Gokhale, S., Johnnidis, J. B., Fu, D., Bell, G. W., Jaenisch, R., & Brummelkamp, T. R. (2007) · Current Biology · doi:10.1016/j.cub.2007.10.039 · Cited by 1,252 · cited 4×
“Although nuclear localization of YAP drives RDC accumulation in healthy rodents [2], it is not known if YAP activation is involved when that process occurs during NAFLD.”
InfluentialMichelotti, G. A., Machado, M. V., & Diehl, A. M. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.183 · Cited by 974 · cited 1×
“Is YAP activated in RDC during NAFLD? If so, are the YAP (+) RDC helping the injured livers to regenerate, or promoting defective, fibrogenic repair? Epidemiologic studies suggest that at least 25% of American adults have some form of NAFLD [6], with about 2% of the general adult population having NAFLD-related cirrho…”
Self-citation
Flagged first, then by citations
1 of the 43 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Omenetti, 2008, Hedgehog signaling regulates EMT during biliary fibrosis in rodents and humans, J Clin Invest, 118, 3331
Cited by
Sorted by citations
Items 101–135 of 135
Mohagheghi, S., Khajehahmadi, Z., & Tavilani, H. (2018) · Avicenna Journal of Medical Biochemistry · doi:10.15171/ajmb.2018.07 · Cited by 4
Islam, M. A., Mawya, J., Salma, U., Kasim, N. H. A., & Haque, N. (2025) · World Journal of Stem Cells · doi:10.4252/wjsc.v17.i11.111090 · Cited by 3
Sun, X., Zhang, Y., Zhang, X. Y., Qin, Q., Hou, Y., Jia, M., Su, X., & Chen, Y. (2026) · Journal of Gastroenterology · doi:10.1007/s00535-026-02372-x · Cited by 3
Abd-Elhafiz, H. I., & Issa, N. M. (2021) · The Egyptian Journal of Hospital Medicine · doi:10.21608/ejhm.2021.139651 · Cited by 3
“YAP is a profibrotic immunohistochemical marker, it is minimally expressed in the normal liver indicating the continuous process of regeneration (20) .”
BackgroundShen, Z., Dai, W., Guo, Y., Wang, J., Shen, B., Li, B., Lu, L., & Cai, X. (2023) · The FASEB Journal · doi:10.1096/fj.202201919r · Cited by 3
Zhang, C., Sui, Y., Liu, S., & Yang, M. J. (2023) · Exploration of Digestive Diseases · doi:10.37349/edd.2023.00029 · Cited by 3
Wang, D., He, D.-W., Lv, T.-T., Zhang, X.-K., Li, Z., & Wang, Z. (2025) · BMC Cancer · doi:10.1186/s12885-025-13676-1 · Cited by 3
Abdallah, R. A., Shaban, M. I., Taie, D. M., Asaad, N. Y., & Badr, A. (2019) · Turkish Journal of Pathology · doi:10.5146/tjpath.2019.01463 · Cited by 3
“In the studied chronic viral hepatitis cases, YAP and TAZ were expressed in hepatocytes which may occur in response to their injury by the virus (33).”
BackgroundResultInfluentialYang, H. S., Jo, Y.-H., Kim, D., Choi, S., Moon, B. G., Lee, Y., Kim, M., Koo, D., & Kim, J. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.11.39 · Cited by 2
Mo, Y., Jiang, Y., Huang, S., Yijiati, A., Zheng, S., Hong, Y., Xian, X., Yu, X., Xiao, Y., 卫秦芝, et al. (2026) · Toxicology · doi:10.1016/j.tox.2026.154493 · Cited by 2
Non-Alcoholic Fatty Liver Disease
Rao, T. R., Pratiksha, B., Navyasri, C., Kalita, D. J., & Alam, S. (2023) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v13i10.6226 · Cited by 3
Abnormal activation of RFC3, A YAP1/TEAD downstream target, promotes gastric cancer progression
Guo, Z., & Guo, L. (2024) · International Journal of Clinical Oncology · doi:10.1007/s10147-024-02478-3 · Cited by 2
An engineered mayhem: YAP/TAZ mechanosignaling and hepatocarcinogenesis in NAFLD
Baffy, G. (2021) · Exploration of Medicine · doi:10.37349/emed.2021.00048 · Cited by 1
“Association between ESRP2 splicing variants and fibrosis was not addressed in this work, but an earlier report from the same group described YAP accumulation in ductular liver cells with progenitor capabilities corresponding with the degree of fibrosis in human and experimentally induced NAFLD [13].”
BackgroundLiu, Y. X., Liang, J., Zeng, W., & Wang, Y. (2022) · PubMed Central · doi:10.12122/j.issn.1673-4254.2022.09.08 · Cited by 1
Hepatic lipid overload potentiates biliary epithelial cell activation via E2FsPreprint
Yıldız, E., Alam, G. E., Perino, A., Jalil, A., Denechaud, P., Huber, K., Lluis Fajas, A., Auwerx, J. H., Sorrentino, G., & Schoonjans, K. (2022) · doi:10.7554/elife.81926.1 · Cited by 1
Chen, X., Zhou, Y., Wang, J., Song, Z., Yang, J., Xu, W., Zhu, D.-X., Sun, Y., Sun, X., Hu, S., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-3767908/v1 · Cited by 1
PCB-associated steatohepatitis and the role of nuclear receptors.
Clair, H. B. (2017) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/2867
Özel, M., Güçlü, K., Helvacı, N., Kılıç, E., Başkol, M., & Başkol, G. (2020) · Turkish Journal of Biochemistry · doi:10.1515/tjb-2019-0397
“Studies on YAP/TAZ pathway and liver fibrosis are relatively new and limited [21] and YAP activation have an crucial role in liver fibrosis.”
Mechanisms of ductular reaction in non-alcoholic steatohepatitis
Chen, Y., Gao, W.-K., Shu, Y.-Y., & Ye, J. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i19.0000 · Cited by 29
Author Response: Hepatic lipid overload potentiates biliary epithelial cell activation via E2Fs
Yıldız, E., Alam, G. E., Perino, A., Jalil, A., Denechaud, P., Huber, K., Fajas, L., Auwerx, J. H., Sorrentino, G., & Schoonjans, K. (2022) · doi:10.7554/elife.81926.1.sa3
Hamidi, T., Jiang, Y., Robinson, T. P., Kronbergs, A., Au, E. D., Rupert, J. E., Zhong, X., Lal, S., Liang, T. W., Robling, A. G., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.01.646698
“Yap1 is a prognostic marker in chronic liver disease and HCC 57-59 .”
Review of roles of RNA-binding proteins on NAFLD and the related pharmaceutical measures
Li, C., Yang, F., Yuan, Z., & Wei, X. (2025) · Biomolecules and Biomedicine · doi:10.17305/bb.2025.12465
Wandji, L. C. N., Saleh, M. B., Sobolewski, C., Amrani, M. E., Bray, F., Boleslawski, E., Eeckhoute, J., Devaux, P.-J., Maggiotto, F., Taront, S., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101580
“Machado et al. observed that the accumulation of duct cells with activated YAP in patients with metabolic dysfunction-associated steatohepatitis (MASH) 30 parallels myofibroblast accumulation and fibrosis progression.”
Hamesch, K., Güldiken, N., Aly, M., Hüser, N., Hartmann, D., Rufat, P., Ziol, M., Remih, K., Lurje, G., Scheiner, B., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13225804
Targeting YAP: mechanistic breakthroughs and therapeutic prospects in reversing organ fibrosis
Fu, K., Cao, M., Wang, Y., Luo, J., & Yuan, W. (2026) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-026-05540-y · Cited by 1
Cluster Effect in Cartilage Formation: Chondrocyte Function, Phenotype, and Molecular Mechanisms
Haider, M. A., Ahmed, A., & Zhang, Q. (2026) · Scientia. Technology, science and society. · doi:10.59324/stss.2026.3(5).05
Wang, P., Li, M., Zhou, Z., Luo, K., Lu, Y., Zhang, Z., Su, J., Zhang, S., Tu, Y., Luo, H., et al. (2026) · Liver International · doi:10.1111/liv.70935
“…mouse models, the expression level of YAP is significantly upregulated and this upregulation is mainly concentrated in the nuclei of ductal reactive cells (DRC) that express progenitor cell markers and its expression level is positively correlated with the degree of liver fibrosis [74].”
Yang, D., Deng, Y., Yin, C., Kang, W., & Song, C. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2026.113665
Metadata
- Authors
- Machado, M. V., Michelotti, G. A., Pereira, T. A., Xie, G., Premont, R., Cortez-Pinto, H., & Diehl, A. M.
- Affiliations
- Duke University (US)
- Duke Medical Center (US)
- Corresponding author
- Diehl, Anna Mae
- ORCID
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2015-10
- Volume
- 63
- Issue
- 4
- Pages
- 962-970
- ISSN
- 0168-8278 (ISSN-L)
- PMC
- PMC4575842
- OpenAlex
- W2130148732
- Cited by
- 135
- References
- 43
- Citations by year
- 2026: 7 · 2025: 15 · 2024: 7 · 2023: 11 · 2022: 21 · 2021: 19 · 2020: 14 · 2019: 13 · 2018: 8 · 2017: 7 · 2016: 11 · 2015: 1
- FWCI
- 5.33
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (5r37aa010154-20)
- National Institute on Alcohol Abuse and Alcoholism (R37 AA-010154)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK0077794, R01DK077794, DK053792, R01DK053792)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Hippo pathway signaling and YAP/TAZ
- Keywords
- YAP, liver fibrosis, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, liver regeneration, Sonic hedgehog, osteopontin, myofibroblasts, hepatocyte injury, liver progenitor cells
- MeSH terms
- YAP-Signaling Proteins, Adult, Animals, Bile Ducts, Intrahepatic, Biopsy, Female, Gene Expression Regulation, Humans, Immunohistochemistry, Liver Cirrhosis, Experimental, Male, Mice, Inbred C57BL, Phosphoproteins, RNA, Messenger, Blotting, Western, Disease Progression, Cell Cycle Proteins, Reverse Transcriptase Polymerase Chain Reaction, Hepatocytes, Adaptor Proteins, Signal Transducing, Mice, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
